# All ETCTN Trials: Updated February 13, 2019

(Includes trials that are in review, approved, and active)

<table>
<thead>
<tr>
<th>CTEP Trial ID</th>
<th>Title</th>
<th>Limited/ETCTN-wide</th>
<th>Radiation Oncology</th>
<th>Disease Area(s)</th>
<th>ClinicalTrials.gov website (if available)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9149</td>
<td>Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, mutations</td>
<td>Solid tumors, mutations</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01827384">https://clinicaltrials.gov/ct2/show/NCT01827384</a></td>
</tr>
<tr>
<td>9466</td>
<td>Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I only)</td>
<td>ETCTN-wide</td>
<td>Skin and other melanoma</td>
<td>Solid tumors, mutations</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT01989585">https://clinicaltrials.gov/ct2/show/NCT01989585</a></td>
</tr>
<tr>
<td>9608</td>
<td>A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors</td>
<td>ETCTN-wide</td>
<td>Gastrointestinal</td>
<td>Gastrointestinal</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02143401">https://clinicaltrials.gov/ct2/show/NCT02143401</a></td>
</tr>
<tr>
<td>9676</td>
<td>A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors</td>
<td>Limited</td>
<td>Melanoma, Genitourinary, Ovarian, Gastrointestinal</td>
<td>Melanoma, Genitourinary, Ovarian, Gastrointestinal</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02298959">https://clinicaltrials.gov/ct2/show/NCT02298959</a></td>
</tr>
<tr>
<td>9681</td>
<td>A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivolpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors</td>
<td>Limited</td>
<td>Genitourinary</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02496208">https://clinicaltrials.gov/ct2/show/NCT02496208</a></td>
</tr>
<tr>
<td>9706</td>
<td>Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02275533">https://clinicaltrials.gov/ct2/show/NCT02275533</a></td>
</tr>
<tr>
<td>9767</td>
<td>An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic</td>
<td>ETCTN-wide</td>
<td>Genitourinary</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03108261">https://clinicaltrials.gov/ct2/show/NCT03108261</a></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Description</td>
<td>Stage</td>
<td>Tumor Type</td>
<td>Link</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>-------</td>
<td>------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>9782</td>
<td>A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors</td>
<td>Limited</td>
<td>Solid tumors, NOS</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02317874">Link</a></td>
<td></td>
</tr>
<tr>
<td>9837</td>
<td>Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin</td>
<td>ETCTN-wide</td>
<td>Solid tumors, NOS, Gastrointestinal, Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02535312">Link</a></td>
<td></td>
</tr>
<tr>
<td>9844</td>
<td>A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors</td>
<td>Limited</td>
<td>Breast</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02453620">Link</a></td>
<td></td>
</tr>
<tr>
<td>9875</td>
<td>Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02572453">Link</a></td>
<td></td>
</tr>
<tr>
<td>9876</td>
<td>Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer</td>
<td>Limited</td>
<td>Breast</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02474173">Link</a></td>
<td></td>
</tr>
<tr>
<td>9881</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Breast, Gastrointestinal, Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02498613">Link</a></td>
<td></td>
</tr>
<tr>
<td>9892</td>
<td>Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02595879">Link</a></td>
<td></td>
</tr>
<tr>
<td>9898</td>
<td>A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02496663">Link</a></td>
<td></td>
</tr>
<tr>
<td>9899</td>
<td>A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors</td>
<td>Limited</td>
<td>Solid tumors, NOS</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02503709">Link</a></td>
<td></td>
</tr>
<tr>
<td>9903</td>
<td>A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02520778">Link</a></td>
<td></td>
</tr>
<tr>
<td>Trial Number</td>
<td>Description</td>
<td>NCT ID</td>
<td>Disease Area</td>
<td>URL</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>9910</td>
<td>A Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02503722">https://clinicaltrials.gov/ct2/show/NCT02503722</a></td>
<td></td>
</tr>
<tr>
<td>9914</td>
<td>A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors</td>
<td>Limited</td>
<td>Solid tumors, NOS</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02631733">https://clinicaltrials.gov/ct2/show/NCT02631733</a></td>
<td></td>
</tr>
<tr>
<td>9924</td>
<td>A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02568553">https://clinicaltrials.gov/ct2/show/NCT02568553</a></td>
<td></td>
</tr>
<tr>
<td>9930</td>
<td>A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02520791">https://clinicaltrials.gov/ct2/show/NCT02520791</a></td>
<td></td>
</tr>
<tr>
<td>9938</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
<td>Limited</td>
<td>Solid tumors, NOS</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02595931">https://clinicaltrials.gov/ct2/show/NCT02595931</a></td>
<td></td>
</tr>
<tr>
<td>9944</td>
<td>Phase 2 Study of M6620 (VX-970) in Combination with Gemcitabine Versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer</td>
<td>ETCTN-wide</td>
<td>Gynecologic</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02595892">https://clinicaltrials.gov/ct2/show/NCT02595892</a></td>
<td></td>
</tr>
<tr>
<td>9947</td>
<td>A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or Without VX-970 in Metastatic Urothelial Carcinoma</td>
<td>ETCTN-wide</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02567409">https://clinicaltrials.gov/ct2/show/NCT02567409</a></td>
<td></td>
</tr>
<tr>
<td>9948</td>
<td>Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer</td>
<td>Limited</td>
<td>Gynecologic</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02627443">https://clinicaltrials.gov/ct2/show/NCT02627443</a></td>
<td></td>
</tr>
<tr>
<td>9950</td>
<td>A Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Head and Neck/Thyroid</td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Phase</td>
<td>Intervention</td>
<td>Type</td>
<td>Condition</td>
</tr>
<tr>
<td>------</td>
<td>------------------------------------------------------------------------</td>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9952</td>
<td>Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Brain, Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02589522">https://clinicaltrials.gov/ct2/show/NCT02589522</a></td>
</tr>
<tr>
<td>9979</td>
<td>Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IpDr) as a Prodrug for IUDR-Mediated Tumor Radiosensitization in Brain Metastases</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Brain</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02993146">https://clinicaltrials.gov/ct2/show/NCT02993146</a></td>
</tr>
<tr>
<td>1002</td>
<td>A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas</td>
<td>ETCTN-wide</td>
<td>Lymphoma, Solid tumors (NOS)</td>
<td></td>
<td><a href="https://clinicaltrials.gov/show/NCT03030417">https://clinicaltrials.gov/show/NCT03030417</a></td>
</tr>
<tr>
<td>1009</td>
<td>A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02936752">https://clinicaltrials.gov/ct2/show/NCT02936752</a></td>
</tr>
<tr>
<td>10013</td>
<td>Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)</td>
<td>ETCTN-wide</td>
<td>Breast</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02883062">https://clinicaltrials.gov/ct2/show/NCT02883062</a></td>
</tr>
<tr>
<td>10014</td>
<td>A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies</td>
<td>ETCTN-wide</td>
<td>Leukemia, Lymphoma, Solid tumors (NOS)</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02862275">https://clinicaltrials.gov/ct2/show/NCT02862275</a></td>
</tr>
<tr>
<td>10015</td>
<td>A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma</td>
<td>ETCTN-wide</td>
<td>Sarcoma</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03148275">https://clinicaltrials.gov/ct2/show/NCT03148275</a></td>
</tr>
<tr>
<td>10017</td>
<td>A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer</td>
<td>ETCTN-wide</td>
<td>Gynecologic</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03206047">https://clinicaltrials.gov/ct2/show/NCT03206047</a></td>
</tr>
<tr>
<td>10020</td>
<td>A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous</td>
<td>Limited</td>
<td>Breast</td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02849496">https://clinicaltrials.gov/ct2/show/NCT02849496</a></td>
</tr>
<tr>
<td>Trial Number</td>
<td>Title</td>
<td>Treatment Details</td>
<td>Primary Site</td>
<td>Location</td>
<td>Link</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>--------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>10021</td>
<td>A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC</td>
<td>ETCTN-wide Radiation Lung</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02888743">https://clinicaltrials.gov/ct2/show/NCT02888743</a></td>
</tr>
<tr>
<td>10026</td>
<td>A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia</td>
<td>Limited Leukemia</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02890329">https://clinicaltrials.gov/ct2/show/NCT02890329</a></td>
</tr>
<tr>
<td>10030</td>
<td>A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia</td>
<td>Limited Leukemia</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02879695">https://clinicaltrials.gov/ct2/show/NCT02879695</a></td>
</tr>
<tr>
<td>10031</td>
<td>A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer</td>
<td>Limited Solid tumors, escalation only, Gynecologic, Breast</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02898207">https://clinicaltrials.gov/ct2/show/NCT02898207</a></td>
</tr>
<tr>
<td>10042</td>
<td>A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases</td>
<td>ETCTN-wide Brain, Lung</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02971501">https://clinicaltrials.gov/ct2/show/NCT02971501</a></td>
</tr>
<tr>
<td>10056</td>
<td>A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma</td>
<td>Limited Radiation Sarcoma</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02923778">https://clinicaltrials.gov/ct2/show/NCT02923778</a></td>
</tr>
<tr>
<td>10057</td>
<td>A Phase II Study of T-VEC Followed by T-VEC + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors</td>
<td>ETCTN-wide Skin and other melanoma</td>
<td></td>
<td></td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02978625">https://clinicaltrials.gov/ct2/show/NCT02978625</a></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Study Description</td>
<td>Phase</td>
<td>Disease Type</td>
<td>URL</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------------</td>
<td>-------</td>
<td>--------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>10061</td>
<td>A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, NOS</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03030378">link</a></td>
<td></td>
</tr>
<tr>
<td>10066</td>
<td>A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)</td>
<td>ETCTN-wide</td>
<td>Gastrointestinal</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03008278">link</a></td>
<td></td>
</tr>
<tr>
<td>10067</td>
<td>A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy</td>
<td>ETCTN-wide</td>
<td>Brain</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT02974621">link</a></td>
<td></td>
</tr>
<tr>
<td>10070</td>
<td>Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors</td>
<td>Limited</td>
<td>Solid tumors, escalation only, Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03366103">link</a></td>
<td></td>
</tr>
<tr>
<td>10075</td>
<td>A Phase 1B Study of AMG-232 in Combination with Decitabine in Acute Myeloid Leukemia</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03041688">link</a></td>
<td></td>
</tr>
<tr>
<td>10076</td>
<td>A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma</td>
<td>Limited</td>
<td>Myeloma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03031730">link</a></td>
<td></td>
</tr>
<tr>
<td>10089</td>
<td>A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03038672">link</a></td>
<td></td>
</tr>
<tr>
<td>10096</td>
<td>A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03317392">link</a></td>
</tr>
<tr>
<td>10100</td>
<td>A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option</td>
<td>ETCTN-wide</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03237780">link</a></td>
<td></td>
</tr>
<tr>
<td>10104</td>
<td>A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer</td>
<td>ETCTN-wide</td>
<td>Gynecologic</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03367741">link</a></td>
<td></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Title</td>
<td>Treatment</td>
<td>Disease/Condition</td>
<td>ClinicalTrials.gov ID</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>------------------------</td>
<td></td>
</tr>
<tr>
<td>10106</td>
<td>A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03309878">https://clinicaltrials.gov/ct2/show/NCT03309878</a></td>
<td></td>
</tr>
<tr>
<td>10107</td>
<td>Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03126630">https://clinicaltrials.gov/ct2/show/NCT03126630</a></td>
<td></td>
</tr>
<tr>
<td>10126</td>
<td>A Pilot Study of Atezolizumab (MPDL3280A) in Combination with Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma</td>
<td>ETCTN-wide</td>
<td>Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03321643">https://clinicaltrials.gov/ct2/show/NCT03321643</a></td>
<td></td>
</tr>
<tr>
<td>10129</td>
<td>A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Brain, Gastrointestinal, Solid tumors (mutations)</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03212274">https://clinicaltrials.gov/ct2/show/NCT03212274</a></td>
<td></td>
</tr>
<tr>
<td>10130</td>
<td>A Phase I Study of Single Agent Tazemetostat in Subjects with Advanced Solid Tumors or B-Cell Lymphomas with Hepatic Dysfunction</td>
<td>ETCTN-wide</td>
<td>Lymphoma, Solid tumors (NOS)</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03217253">https://clinicaltrials.gov/ct2/show/NCT03217253</a></td>
<td></td>
</tr>
<tr>
<td>10131</td>
<td>Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated/Amplified Advanced Solid Tumors, Potentially Amenable to Docetaxel</td>
<td>Limited</td>
<td>Solid tumors, mutations and escalation only, Breast, Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03218826">https://clinicaltrials.gov/ct2/show/NCT03218826</a></td>
<td></td>
</tr>
<tr>
<td>10132</td>
<td>A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03345784">https://clinicaltrials.gov/ct2/show/NCT03345784</a></td>
<td></td>
</tr>
<tr>
<td>10136</td>
<td>A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification</td>
<td>ETCTN-wide</td>
<td>Solid tumors, mutations</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03253679">https://clinicaltrials.gov/ct2/show/NCT03253679</a></td>
<td></td>
</tr>
<tr>
<td>10144</td>
<td>A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects</td>
<td>ETCTN-wide</td>
<td>Genitourinary</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03375307">https://clinicaltrials.gov/ct2/show/NCT03375307</a></td>
<td></td>
</tr>
<tr>
<td>10145</td>
<td>Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas</td>
<td>Limited</td>
<td>Lymphoma, Solid tumors (NOS)</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03502733">https://clinicaltrials.gov/ct2/show/NCT03502733</a></td>
<td></td>
</tr>
<tr>
<td>10146</td>
<td>Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine</td>
<td>ETCTN-wide</td>
<td>Breast</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03606967">https://clinicaltrials.gov/ct2/show/NCT03606967</a></td>
<td></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Title</td>
<td>Phase</td>
<td>Disease</td>
<td>Details</td>
<td>Sponsor</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------</td>
<td>-------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>10147</td>
<td>A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML</td>
<td>II</td>
<td>Leukemia</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10170</td>
<td>A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies</td>
<td>II</td>
<td>Solid tumors, mutations</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10181</td>
<td>A Phase II Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer</td>
<td>II</td>
<td>Gastrointestinal</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10183</td>
<td>A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma</td>
<td>Pilot</td>
<td>Genitourinary</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10184</td>
<td>Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)</td>
<td>N/A</td>
<td>Radiation</td>
<td>Limited, Head and Neck/Thyroid</td>
<td></td>
</tr>
<tr>
<td>10186</td>
<td>A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma</td>
<td>I/II</td>
<td>Brain</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10191</td>
<td>Phase 2 Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer</td>
<td>II</td>
<td>Genitourinary</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10193</td>
<td>Phase 2 Study of Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma</td>
<td>II</td>
<td>Lymphoma</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>10195</td>
<td>A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Breast Cancer</td>
<td>II</td>
<td>Breast</td>
<td>ETCTN-wide</td>
<td></td>
</tr>
<tr>
<td>Trial Number</td>
<td>Description</td>
<td>Phase</td>
<td>Primary Disease</td>
<td>Study URL</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>10200</td>
<td>Combination Pinometostat and 5-Azacitidine for the Treatment of Patients with Relapsed / Refractory Acute Myeloid Leukemia, or Newly Diagnosed Patients who are Ineligible for or Unwilling to Undergo Intensive Therapy, who Harbor an 11q23 Rearrangement</td>
<td>Limited</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03701295">https://clinicaltrials.gov/ct2/show/NCT03701295</a></td>
<td></td>
</tr>
<tr>
<td>10204</td>
<td>Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)</td>
<td>ETCTN-wide</td>
<td>Solid tumors, NOS, Lymphoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03816345">https://clinicaltrials.gov/ct2/show/NCT03816345</a></td>
<td></td>
</tr>
<tr>
<td>10208</td>
<td>A Phase I/II study of Anetumab Rvatsamine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemicitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma</td>
<td>ETCTN-wide</td>
<td>Gastrointestinal</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03816358">https://clinicaltrials.gov/ct2/show/NCT03816358</a></td>
<td></td>
</tr>
<tr>
<td>10212</td>
<td>A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03724084">https://clinicaltrials.gov/ct2/show/NCT03724084</a></td>
<td></td>
</tr>
<tr>
<td>10214</td>
<td>Immune Checkpoint Blockade for Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers</td>
<td>Limited</td>
<td>Skin and other melanoma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03816332">https://clinicaltrials.gov/ct2/show/NCT03816332</a></td>
<td></td>
</tr>
<tr>
<td>10217</td>
<td>A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, mutations and escalation only</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03842228">https://clinicaltrials.gov/ct2/show/NCT03842228</a></td>
<td></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Trial Title</td>
<td>ETCTN-wide</td>
<td>Disease</td>
<td>ClinicalTrials.gov</td>
<td>Notes</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------</td>
<td>--------------------------</td>
<td>---------------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>10219</td>
<td>Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma</td>
<td>ETCTN-wide</td>
<td>Myeloma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03798678">https://clinicaltrials.gov/ct2/show/NCT03798678</a></td>
<td>Not available at this time.</td>
</tr>
<tr>
<td>10220</td>
<td>A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, mutations, Brain</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10221</td>
<td>Phase I/II Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, mutations</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10222</td>
<td>A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Gastrointestinal, Solid tumors (mutations)</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10237</td>
<td>A Phase 1 Study of TAK-243 for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03816319">https://clinicaltrials.gov/ct2/show/NCT03816319</a></td>
<td></td>
</tr>
<tr>
<td>10240</td>
<td>Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (Cabonivolpi) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy</td>
<td>ETCTN-wide</td>
<td>Head and Neck/Thyroid</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10244</td>
<td>Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas</td>
<td>ETCTN-wide</td>
<td>Lymphoma, Solid tumors (escalation only)</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10246</td>
<td>A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03772925">https://clinicaltrials.gov/ct2/show/NCT03772925</a></td>
<td></td>
</tr>
<tr>
<td>10247</td>
<td>A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03745352">https://clinicaltrials.gov/ct2/show/NCT03745352</a></td>
<td></td>
</tr>
<tr>
<td>10248</td>
<td>A Phase 1/2 Study of MLN9708 (Ixazomib [I]), Venetoclax (V), and Dexamethasone (D)</td>
<td>ETCTN-wide</td>
<td>Myeloma</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Description</td>
<td>Phase</td>
<td>Condition</td>
<td>Status</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-------------</td>
<td>-------</td>
<td>-----------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>10249</td>
<td>MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial</td>
<td>ETCTN-wide</td>
<td>Myeloma</td>
<td><a href="https://clinicaltrials.gov/ct2/show/NCT03770260">https://clinicaltrials.gov/ct2/show/NCT03770260</a></td>
<td></td>
</tr>
<tr>
<td>10250</td>
<td>A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma</td>
<td>ETCTN-wide</td>
<td>Gynecologic</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10264</td>
<td>The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10266</td>
<td>A Phase 2 Study of MLN4924 (Pevonedistat) in Combination with Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated with Immunotherapy</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10268</td>
<td>Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer</td>
<td>ETCTN-wide</td>
<td>Lung</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10273</td>
<td>A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia</td>
<td>ETCTN-wide</td>
<td>Leukemia</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10275</td>
<td>A Phase 1/2 Study of M3814 in Combination with SBRT for the Treatment of Localized Pancreatic Adenocarcinoma</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Gastrointestinal</td>
<td>Not available at this time.</td>
</tr>
<tr>
<td>10276</td>
<td>A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies</td>
<td>ETCTN-wide</td>
<td>Radiation</td>
<td>Gastrointestinal, Solid tumors (dose escalation)</td>
<td>Not available at this time.</td>
</tr>
<tr>
<td>10287</td>
<td>A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)</td>
<td>ETCTN-wide</td>
<td>Breast</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>Trial ID</td>
<td>Title</td>
<td>Sponsor</td>
<td>Disease(s)</td>
<td>Availability</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------</td>
<td>-----------------------------------</td>
<td>----------------------</td>
<td></td>
</tr>
<tr>
<td>10291</td>
<td>A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer</td>
<td>ETCTN-wide</td>
<td>Radiation Breast</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10292</td>
<td>Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors</td>
<td>ETCTN-wide</td>
<td>Solid tumors, NOS</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10295</td>
<td>A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma</td>
<td>ETCTN-wide</td>
<td>Solid tumors (mutations)</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10296</td>
<td>Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation, PTEN mutation or PTEN loss</td>
<td>ETCTN-wide</td>
<td>Breast</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10299</td>
<td>A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients</td>
<td>ETCTN-wide</td>
<td>Lymphoma, Solid tumors, NOS</td>
<td>Not available at this time.</td>
<td></td>
</tr>
<tr>
<td>10302</td>
<td>Phase II Trial of Radium-223 in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer</td>
<td>ETCTN-wide</td>
<td>Radiation Breast</td>
<td>Not available at this time.</td>
<td></td>
</tr>
</tbody>
</table>